Division of Novartis AG
Latest From Sandoz Inc.
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Greg Nulty, VP, Head, Finance & CFO
Patrick Genestin, VP, Bus. Dev. & Licensing
Carlos Sattler, MD, VP, Clin. Dev. & Medical Affairs
Scott Smith, VP, Commercial Operations, US
Anthony Maffia, III, VP, Regulatory Affairs
Carol Lynch, Pres.
- Contact Info
Phone: (609) 627-8500
100 College Rd. West
Princeton, NJ 08540
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.